The PurpleLab®

Life Sciences

Research

Characterize the real-world CAR-T patient population by describing demographic and social drivers of health (SDOH) attributes at the time of therapy initiation.

Whitepapers

The U.S. generic drug supply is at a critical crossroad. With over 60% of generics made abroad, we face a fragile supply chain. This whitepaper analyzes how immediate tariffs to boost domestic manufacturing risk raising patient costs and disrupting access, and outlines the strategic, phased approach needed to secure our drug supply for the long term.

Research

This study was run to characterize patient demographics, cancer indications, treatment patterns, and survival outcomes in a large cohort of patients receiving ADC therapy.

Articles

Biomarker testing can drastically extend survival across multiple cancer types. But gaps in adoption persist. Are payers, pharma and policymakers doing enough to ensure these tests actually having an impact in the real world? PurpleLab recently conducted a study, Maximizing Survival: The Real-World Impact of Biomarker Testing in Metastatic NSCLC, to shed light on how…

Articles

As the healthcare industry continues to face data challenges, PurpleLab® is making significant investments in its data and infrastructure to reinforce its position as a trusted leader in real-world data (RWD). We’ve recently secured several new data sources that will dramatically improve the comprehensiveness and composition of our data.(RWD) and real-world evidence (RWE) earlier in the product lifecycle to inform decision-making.

Articles

Although randomized controlled trials remain a cornerstone of evidence generation, pharmaceutical and biotech companies are increasingly recognizing the necessity of leveraging real-world data
(RWD) and real-world evidence (RWE) earlier in the product lifecycle to inform decision-making.

Articles

Biomarker testing guides selection of targeted therapies in non–small cell lung cancer (NSCLC). Despite its clinical importance, the extent of provider variation in biomarker testing practices and its correlation with patient outcomes has not been thoroughly explored.

Articles

Clinical trials are designed to evaluate the safety and efficacy of new therapies or medical devices. During these trials, evidence is gathered to determine if the asset is safe for patients, providing the intended benefit at the appropriate dosage, as well as identifying and minimizing any potential side effects.

Videos

In pharmaceutical development, where most therapies never reach the market, early and strategic data investments can make all the difference.